









Markets
/
Stocks
/
nasdaq-lixt
/

Lixte Biotechnology Holdings Inc

LIXT

4.000USD

-0.100-2.44%

Market hours （ET）Quotes delayed by 15 min

11.03MMarket Cap

LossP/E TTM



Lixte Biotechnology Holdings Inc

4.000

-0.100-2.44%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lixte Biotechnology Holdings Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lixte Biotechnology Holdings Inc's Score

Industry at a Glance

Industry Ranking

225 / 407

Overall Ranking

446 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Lixte Biotechnology Holdings Inc Highlights

StrengthsRisks

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Undervalued

The company’s latest PE is -3.19, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 309.34K shares, decreasing 25.53% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 25.69K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.76.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Lixte Biotechnology Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 5.91, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.19, which is -85.07% below the recent high of -0.48 and -48.45% above the recent low of -4.74.

Score

Industry at a Glance

Previous score

5.91

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 225/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 5.85, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 4.83 and the support level at 3.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

-0.93

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(6)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.017

Sell

RSI(14)

40.299

Neutral

STOCH(KDJ)(9,3,3)

36.395

Sell

ATR(14)

0.357

Low Volatility

CCI(14)

-136.533

Sell

Williams %R

75.325

Sell

TRIX(12,20)

-0.623

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

4.298

Sell

MA10

4.286

Sell

MA20

4.399

Sell

MA50

4.724

Sell

MA100

3.932

Buy

MA200

2.700

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 5.42%, representing a quarter-over-quarter decrease of 81.48%. The largest institutional shareholder is The Vanguard, holding a total of 25.69K shares, representing 0.45% of shares outstanding, with 94.47% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Orca Capital GmbH

120.01K

Hightower Advisors, LLC

99.43K

Intracoastal Capital, L.L.C.

42.00K

The Vanguard Group, Inc.

Star Investors

5.38K

Ethos Financial Group, LLC

24.81K

Geode Capital Management, L.L.C.

20.70K

-10.14%

Atlas Legacy Advisors, LLC

13.77K

+8.37%

Van Der Baan (Bastiaan Jeroen)

11.00K

+2.52%

Tower Research Capital LLC

3.33K

UBS Financial Services, Inc.

1.11K

-86.59%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.06, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.